{"name":"UnicoCell Biomed CO. LTD","slug":"unicocell-biomed-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ELIXCYTE","genericName":"ELIXCYTE","slug":"elixcyte","indication":"Solid tumors (specific indications under investigation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"ELIXCYTE","genericName":"ELIXCYTE","slug":"elixcyte","phase":"phase_3","mechanism":"ELIXCYTE is an autologous cell therapy that expands and reinfuses a patient's own immune cells to enhance anti-tumor immunity.","indications":["Solid tumors (specific indications under investigation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPNVRSMUtERVNLT3BpVk9iVkJnS1ZNdFc5QmZIOXVtcTdFcFVtaWtqRnB5WVNpRGp1WE8yNkYwYUMyZFlnaXAyaG5abXlPZS0tZXdIWlZvTmZ0ci1od0VHZkM1cE41bXRmaWFjVzFwcTVZbFdISWMwZ0gxc0hYZW9KZnJBLV9aYXQzdXV3S2E2c0pmOElDRnNzRlJiOHlxMURoYUdjR0tnNUFzNUdZSTNOUGpDRFJwU0lFY2RHTnpuQWlfUDhiVm04RXVDVlFFUV9IczM2cEtlWDJWbVZTQlR2dDkzOURkZ29IWUZuUFJHbll2TXhuYU42ZFRpSVloVG9QVE0tSl93Z21sdVNRLXNTcURZdUNmUGc2czRIcTZETTUxbllPTTNjV1FuNG5MWWQzVTA3V3Q2SVFLZTE5TGRFeFpwQ0l1eTlQbUxsbl9uYw?oc=5","date":"2026-03-25","type":"trial","source":"Barchart.com","summary":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds DelveInsight | Biosplice Therapeutics, Regeneron Pharmaceuticals - Barc","headline":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNZmlKVDJlSEtYNGh3QnRTZXliRFRPR3VULThBVlhJRzNZRHpsbkQwbU95bjI0aWtoUDNITXowWnc1Ny1BUEgwbGtIdk5SREhRdVpMZ2pId3BPLTdEeHlkRV9Jc3ZjVXc3SFgzYmxVRjJvbnVUNmVmMURBLUtDVU44UllmY253cXFmcER6YVlfcmhKT3dra01MN1ZXcG9SRUxfS1BDQmNEVXZIaFlOMVhJeTg3WGJUSF91MGN0bXl3?oc=5","date":"2026-03-03","type":"pipeline","source":"Weekly Voice","summary":"Resilient Roofing Solutions: The Benefits of Silicone Roof Coatings in Extreme Weather Conditions - Weekly Voice","headline":"Resilient Roofing Solutions: The Benefits of Silicone Roof Coatings in Extreme Weather Conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOZlJiMnRjTzZuTGFPQUdmU2g1UEpFdnE0YVJuS1ozOHpFYWFWc19rNHFRNkF6Z1dYX2dPSzJrVDNsOE5RSXh3NFZzWFlMdHotR2xURzFPaW81ZUZacGdsNFNXS1piWElJaHdPcTZLWWpNeUc1SzZjNzFQa2lkQlRWOGk4aDhOYml5aTJCTUhha0J2R3ZCdmRoOWZhMTVNNXVwMzVzak1ibEF0VkFTOTVRZGIzc0diQURWNEpIMzI0SlRuUWhCSzM2MXRjSkFheklGczU4UmNaZVN3WmZFZnRLTG5ZTU5BU2ZkRjlHb2JOTmkwUWl1Tl9IdjR5X3d3bGV0YXkwM1FCei1uMVpEa1FCSkxHaUVkMHlRdW9FcFo0R0plRWpLcnVZWUw2aEluWXRlYUE?oc=5","date":"2025-04-24","type":"trial","source":"GlobeNewswire","summary":"Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ - GlobeNewswire","headline":"Sarcopenia Clinical Trial Pipeline Appears Robust With 18+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNVEJwUGRkeHZzLVdhaV9RRmdGbThzM0hHc0RTOTR0dzdtZUZYb1hQckhxMDNGRDVMem1rOVBkRm5ldERIN0xSY18xMXc1MGtOWW9QQVZrWDBBZ24xblFjRjhlaTg5MTVPU3hEUmNBNUJUZUFLTloyTGdvTkFpX1FiM0l2ajQ4U05zamtUZWpZSHhjaXRUeDFTVExtMUVTV1FsVno3TmFCREdLb0JiOU1IV3gxLTRrNmlNYnZtWmxNcDkzT1ZvMG9xd01zYWNNTGpGeUJEb2txcU9XR3JNNFZweGRyUUUwYTFIeFd3?oc=5","date":"2024-11-14","type":"pipeline","source":"GlobeNewswire","summary":"Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight - GlobeNewswire","headline":"Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPejRGZWJpTmZNNWVJdm9YTHBrVk5xakRVV1NsbVhjQUxiVm9rbTc5OXBkMUpfVmRGMW9MOFpCcUliakR0emU4UjBrWUNIZWZQRlhoVEU1ODhHUWcxOGdkY3hIektmaGRoVDJMX1hTSllXTnBjbi1qYlE3cHY5QTN1SW1VcHpnc1NJbDdpcElkZW5JbmNiZ24taE5sVWRWZ0VIVkNYOHdvSTZXYVpKOXZDSFpNLVFlOEZJaFFxQkFLckM4WlA1aTJwT01XcW4xREsya0JYT1JJcHRHYmJwMExJNzRmeEYzZU1kTVNNdm5kVUlzN2xvcEJpWG8wNnBoU000N2Z4N2FvSU5pY29zeVFHNkVMbUU3RzhSbFh0a0hQNVE0eVFOQk4wdjBZYlg?oc=5","date":"2024-08-15","type":"pipeline","source":"GlobeNewswire","summary":"Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire","headline":"Global Non-Steroidal Anti-Inflammatory Drugs Market is","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}